Search results
Showing 916 to 930 of 1284 results for social care
NICE has developed a medtech innovation briefing (MIB) on Stockholm3 for prostate cancer screening .
Guide to the technology appraisal and highly specialised technologies appeal process (PMG41)
This guide outlines the appeal process for the technology appraisal and highly specialised technologies guidance. It sets out the process that NICE follows for appeals and provides guidance for those who wish to make an appeal or who are considering doing so
Digital technologies for managing non-specific low back pain: early value assessment (HTG712)
Early value assessment (EVA) guidance on digital technologies for managing non-specific low back pain in people 16 years and over.
Spesolimab for treating generalised pustular psoriasis flares (TA1070)
Evidence-based recommendations on spesolimab (Spevigo) for treating generalised pustular psoriasis flares in adults.
Evidence-based recommendations on fremanezumab (Ajovy) for preventing migraine in adults.
The role of parents in the treatment of children and young people with social anxiety disorder:- What is the best way of involving...
Evidence-based recommendations on lumasiran (Oxlumo) for primary hyperoxaluria type 1 in people of all ages.
NICE has developed a medtech innovation briefing (MIB) on Bindex for investigating suspected osteoporosis .
Evidence-based recommendations on tezepelumab (Tezspire) for treating severe asthma in people 12 years and over.
Evidence-based recommendations on molnupiravir (Lagevrio) for treating mild to moderate COVID-19 in adults who have a positive SARS-CoV-2 test.
Relugolix–estradiol–norethisterone for treating symptoms of endometriosis (TA1057)
Evidence-based recommendations on relugolix–estradiol–norethisterone (Ryeqo) for treating symptoms of endometriosis in adults of reproductive age.
Show all sections
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency (HST26)
Evidence-based recommendations on eladocagene exuparvovec (Upstaza) for treating aromatic L-amino acid decarboxylase deficiency in people 18 months and over.
Talimogene laherparepvec for treating unresectable metastatic melanoma (TA410)
Evidence-based recommendations on talimogene laherparepvec (Imlygic) for treating unresectable metastatic melanoma in adults when systemically administered immunotherapies are not suitable.
NG61/2 Question Perinatal palliative care:- What impact does timely perinatal palliative care have on the experience of...
This interim process statement has been produced to guide the development of good practice guidance. It provides an overview of the key process principles and describes all stages of the development of good practice guidance